null

VHL PAT82B10AT Monoclonal Antibody [PAT82B10AT] (CPAB0687)

SKU:
CPAB0687
Product Type:
Antibody
Antibody Type:
Monoclonal Antibody
Reactivity:
Universal
Host Species:
Mouse
Isotype:
IgG2b
Clone:
PAT82B10AT
Applications:
WB
ELISA
€149

Description

system_update_alt Datasheet

VHL PAT82B10AT Monoclonal Antibody [PAT82B10AT] (CPAB0687)

The VHL Polyclonal Antibody (CPAB0687) is a valuable tool for researchers studying the Von Hippel-Lindau (VHL) protein, a key player in the regulation of cell growth and division. This antibody, produced in rabbits, is highly specific to human samples and is suitable for use in Western blotting applications. By binding to the VHL protein, this antibody allows for the detection and analysis of VHL expression in a variety of cell types, making it an essential reagent for studies in cancer biology and tumor suppression mechanisms.

The VHL protein is a tumor suppressor that is commonly mutated in cancer, particularly in clear cell renal cell carcinoma. Understanding the role of VHL in controlling cell proliferation and angiogenesis is crucial for developing targeted therapies for VHL-deficient tumors. The VHL Polyclonal Antibody provides researchers with a reliable tool for investigating the expression and function of VHL in cancer cells, contributing to the development of novel treatment strategies for VHL-associated malignancies.

Product Name:VHL PAT82B10AT Antibody
Product Sku:CPAB0687
Size:5μg
Host Species:Mouse
Immunogen:Anti-human VHL mAb, is derived from hybridization of mouse F myeloma cells with spleen cells from BALB/c mice immunized with a recombinant human VHL protein 1-154 amino acids purified from Ecoli.
Clone:PAT82B10AT.
Reactivity:Other bodies
Applications:Western Blot, ELISA
Purification Method:VHL antibody was purified from mouse ascitic fluids by protein-G affinity chromatography.
Isotype:IgG2b
Background:Von Hippel-Lindau disease is a dominant inherited syndrome characterized by the predisposition to develop various kinds of benign and malignant tumors, including clear cell renal carcinomas, pheochromocytomas and hemangioblastomas of the central nervous system and retina. VHL syndrome is caused by germline mutation in the VHL tumor suppressor, and VHL tumors are associated with loss or mutation of the remaining wild-type allele. VHL has two domains: a roughly 100-residue NH2-terminal domain rich in b sheet (b-domain) and a smaller a-helical domain (a-domain), held together by two linkers and a polar interface. VHL protein is also involved in the degradation of hypoxia-inducible factor (HIF).
Synonyms:Von Hippel-Lindau disease tumor suppressor, pVHL, Protein G7, VHL, RCA1, VHL1, HRCA1.
Storage Buffer:For periods up to 1 month store at 4°C, for longer periods of time, store at -20°C. Prevent freeze thaw cycles.

Related Products